Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (“ProDERM Study”)

INTRODUCTION: Dermatomyositis (DM) is an inflammatory myopathy characterized by distinct skin manifestations and muscle weakness. Intravenous immunoglobulin (IVIg) has been used off-label as adjuvant therapy in DM, but is not indicated for DM, due to lack of proven efficacy in a large randomized con...

Descripción completa

Detalles Bibliográficos
Autores principales: Aggarwal, Rohit, Charles-Schoeman, Christina, Schessl, Joachim, Dimachkie, Mazen M., Beckmann, Irene, Levine, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4000
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793357/
https://www.ncbi.nlm.nih.gov/pubmed/33429735
http://dx.doi.org/10.1097/MD.0000000000023677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793357/
https://www.ncbi.nlm.nih.gov/pubmed/33429735
http://dx.doi.org/10.1097/MD.0000000000023677

Ejemplares similares